Wedbush Has Optimistic Outlook of TSE:FRX FY2025 Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX) – Equities research analysts at Wedbush boosted their FY2025 EPS estimates for Fennec Pharmaceuticals in a report released on Monday, March 10th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn $0.79 per share for the year, up from their previous forecast of $0.66. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ FY2027 earnings at $4.10 EPS.

Separately, Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.

Fennec Pharmaceuticals Price Performance

FRX stock opened at C$9.26 on Wednesday. The company has a market capitalization of C$178.58 million, a P/E ratio of -156.86 and a beta of 0.25. Fennec Pharmaceuticals has a twelve month low of C$5.65 and a twelve month high of C$15.20. The business has a 50 day simple moving average of C$9.19 and a 200-day simple moving average of C$7.90. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83.

Insider Buying and Selling

In other news, Director Rostislav Christov Raykov sold 10,000 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of C$8.76, for a total value of C$87,552.00. Insiders sold a total of 21,186 shares of company stock valued at $196,017 over the last three months. 16.20% of the stock is currently owned by company insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.